Business context and reporting period
Evotec SE is a Germany-based drug discovery and development partner serving pharmaceutical and biotechnology companies. This Form 20-F reports the fiscal year ended December 31, 2021, under IFRS; it is an annual report, not a standalone Q4 filing. The supplied filing text does not provide clear standalone fourth-quarter financial results.
Evotec operates through EVT Execute, primarily fee-for-service and FTE work, and EVT Innovate, which includes internal R&D and partnered programs with potential milestone and royalty income. In November 2021, the company completed its U.S. ADS offering, raising net proceeds of €403.1 million.
Financial results and liquidity
| Metric | 2021 | 2020 | Change / context |
|---|---|---|---|
| Revenue | €618.0 million | €500.9 million | Up 23.4% |
| Gross profit / margin | €151.5 million / 24.5% | €125.7 million / 25.1% | Profit rose; margin eased |
| Operating income | €41.0 million | €48.6 million | Down 15.6% |
| Net income | €215.5 million | €6.3 million | Primarily boosted by investment fair-value gains |
| Adjusted EBITDA | €107.3 million | €106.7 million | Up 0.6%; non-IFRS measure |
| Operating cash flow | €122.2 million | €44.7 million | Increased year over year |
| Cash used in investing activities | €243.9 million | €155.1 million | Included €118.9 million of property and equipment purchases |
Revenue growth reflected higher service and FTE revenue, increased milestone revenue, and materials recharges. Milestone and license revenue rose to €49.5 million from €17.1 million, including milestones from BMS and Takeda. EVT Execute represented 76% of third-party revenue; EVT Innovate represented 24%.
Net income included a €223.8 million gain from investment measurement, mainly relating to Exscientia after financing rounds and its U.S. IPO. It is not a measure of recurring operating performance. Evotec also recorded €11.9 million of impairment losses on equity-method investments and €0.7 million of intangible-asset impairment.
At year-end, cash and cash equivalents were €699.3 million and investments were €158.9 million, totaling €858.2 million. Loan liabilities were €362.5 million and lease liabilities €150.4 million. The company reported net cash of €186.4 million under its stated definition, which deducts loans and lease obligations from cash and cash equivalents. Equity was €1.38 billion, or 61.6% of total assets. Operating cash flow benefited from increased contract liabilities and payables; receivables and other operating assets also increased.
Material changes versus the prior period
- Revenue increased 23.4%, while adjusted EBITDA was broadly flat and operating income declined.
- Gross margin decreased from 25.1% to 24.5%, reflecting Redmond J.POD start-up and capacity costs, foreign exchange effects, and the end of Toulouse-related Sanofi payments; higher milestone revenue partly offset these factors.
- SG&A rose 37% to €105.4 million, primarily due to increased headcount, U.S. listing costs, audit and insurance costs, and investment in IT and strategic projects. R&D expenses increased 12.9% to €72.2 million.
- Cash and investments increased substantially following the U.S. offering. The offering also increased issued shares to 176.6 million at year-end.
- The Exscientia accounting change and valuation gains drove the sharp increase in reported net income; the gain is excluded from Evotec’s adjusted EBITDA measure.
Outlook, commentary and risks
Management expected fee-for-service and FTE-based business to grow at a mid- to high-single-digit rate in the near term. Its strategic goal was to exceed 170 pipeline assets by the end of 2025, with first royalties expected in 2025. These are management targets, not guaranteed outcomes. The company planned significant investment, including 2022 capital expenditure of €75–80 million for replacement and growth, additional €20–25 million to complete Redmond J.POD work, and approximately €180 million for the Toulouse J.POD project across 2022 and 2023.
Redmond J.POD became operational in August 2021; Toulouse construction was planned, with completion targeted by 2024. Management described liquidity risk as low and said it had sufficient liquidity for current plans, while noting that future spending or strategic opportunities could require additional financing. Evotec reported compliance with loan covenants and no secured loans.
Key risks include failure or delay in drug discovery and partner clinical development; termination of projects or customer relationships; reliance on milestone, licensing and royalty outcomes; customer concentration; competition; execution and integration risks from growth and investment; foreign-exchange exposure; tax-credit uncertainty; and cyber, data-protection, quality and regulatory risks. The three largest customers contributed 25% of revenue, with BMS alone contributing €98.6 million. The company cited higher energy, transport and supply-chain risks related to the Russia/Ukraine conflict. COVID-19 had limited adverse financial impact in 2021, but remained a potential source of disruption.
After year-end, Bayer elected to discontinue development of eliapixant; Evotec stated that it could regain rights to the P2X3 assets on request and would evaluate its options. Management reported no risks that, alone or in aggregate, currently threatened the company’s continued existence. Disclosure controls were assessed as effective at year-end; however, the filing did not include management’s ICFR assessment or an auditor attestation, citing transition relief for a newly registered company.
Important facts for investors to verify
- Review the audited financial statements and notes for the Exscientia valuation gain, the equity-investment impairments, and the cash-flow reconciliation; reported net income substantially reflects non-operating investment gains.
- Confirm the company’s precise debt and liquidity position, including lease liabilities, loan maturities, available credit lines, and the distinction between reported cash and investments and management’s net-cash definition.
- Track whether revenue growth converts into improved operating income, adjusted EBITDA, gross margin, and operating cash flow as J.POD facilities and other capacity investments mature.
- Assess partner progress, pipeline attrition, royalty and milestone assumptions, and the impact of Bayer’s decision on eliapixant and related assets.
- Monitor customer concentration, procurement and energy costs, planned Toulouse investment and funding, and Evotec’s subsequent U.S. internal-control reporting.